Lutetium-177 Market Lutetium-177 Market Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Lutetium-177 Market by Form (Carrier ...

ANSTO congratulated the Peter Macallum Cancer Centre led team, who recently reported the remarkable results of late-stage ...

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes ...

Cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with previously treated, ...

Just two years into its existence, radioisotope producer PanTera has drawn 93 million euros ($102.5 million) in an ...

Not only does lutetium-177-PSMA-617 lower PSA levels in men with metastatic prostate cancer (mCRPC), PSA decline correlates with outcomes, research shows.

A new type of prostate cancer therapy that is used only in late-stage treatment where conventional therapy has failed has ...

There is a wide selection of therapies available for advanced prostate cancer treatment, but the optimal strategy for them is ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more efficient, effective, and patient-friendly.

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.

Molecular Targeting Technologies, Inc. (MTTI) will collaborate with Brookline Capital Markets at the upcoming 2nd Targeted ...